Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200306712> ?p ?o ?g. }
- W4200306712 endingPage "6316" @default.
- W4200306712 startingPage "6316" @default.
- W4200306712 abstract "Patients with anaplastic large cell lymphoma (ALCL) rarely develop a leukemic phase of the disease. The reported leukemic ALCL cases are almost all ALK-positive, which are frequently associated with small cell morphology, t(2;5)(p23;q35), and a poorer prognosis. Rare leukemic ALK-negative ALCL cases have been reported. In the present study, we investigated the clinical and pathologic features and outcomes of nine patients with leukemic ALK-negative ALCL and compared these features with 39 patients without leukemic disease. Compared with the non-leukemic ALK-negative ALCL group, patients with leukemic disease more often had absolute lymphocytosis (50% vs. 0%, p = 0.008), thrombocytopenia (60% vs. 11%, p = 0.03), bone marrow involvement (50% vs. 14%, p = 0.04), and CD7 positivity (71% vs. 19%, p = 0.02). Four of five (80%) patients with leukemic ALK-negative ALCL had a complex karyotype, which was significantly higher than that of the patients in the non-leukemic group. A fluorescence in situ hybridization for TP53 was performed on six leukemic ALK-negative ALCL cases and all (100%) had TP53 deletion. There were no significant differences in the other clinicopathologic features, treatment, and complete remission rates between patients in the leukemic versus non-leukemic group (all p > 0.05). The median follow-up of this cohort was 18 months with a range of 0.3-140 months. Eight of nine (90%) patients with leukemic ALK-negative ALCL died, and their overall survival was significantly shorter than that of the patients with non-leukemic disease (median 15.5 vs. 60 months, p = 0.001). In conclusion, we show that the leukemic phase of ALK-negative ALCL is associated with high-risk biologic features and, in particular, a complex karyotype and TP53 deletion. Compared with the non-leukemic ALK-negative ALCL patients, the patients with a leukemic phase of disease have poorer survival and may require more aggressive treatment." @default.
- W4200306712 created "2021-12-31" @default.
- W4200306712 creator A5000027373 @default.
- W4200306712 creator A5006583715 @default.
- W4200306712 creator A5012163855 @default.
- W4200306712 creator A5016734314 @default.
- W4200306712 creator A5018989526 @default.
- W4200306712 creator A5025198232 @default.
- W4200306712 creator A5038345056 @default.
- W4200306712 creator A5043947276 @default.
- W4200306712 creator A5044226126 @default.
- W4200306712 creator A5046597133 @default.
- W4200306712 creator A5055404021 @default.
- W4200306712 creator A5088881526 @default.
- W4200306712 creator A5089295627 @default.
- W4200306712 creator A5090832029 @default.
- W4200306712 date "2021-12-16" @default.
- W4200306712 modified "2023-09-25" @default.
- W4200306712 title "The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis" @default.
- W4200306712 cites W1929194486 @default.
- W4200306712 cites W1929938813 @default.
- W4200306712 cites W1979487073 @default.
- W4200306712 cites W1988349686 @default.
- W4200306712 cites W1989607823 @default.
- W4200306712 cites W1991407381 @default.
- W4200306712 cites W1992099424 @default.
- W4200306712 cites W1992708996 @default.
- W4200306712 cites W1994982832 @default.
- W4200306712 cites W1995244321 @default.
- W4200306712 cites W2034954005 @default.
- W4200306712 cites W2045179620 @default.
- W4200306712 cites W2052578245 @default.
- W4200306712 cites W2054004870 @default.
- W4200306712 cites W2060447125 @default.
- W4200306712 cites W2064454773 @default.
- W4200306712 cites W2066811439 @default.
- W4200306712 cites W2080157106 @default.
- W4200306712 cites W2088900228 @default.
- W4200306712 cites W2095996837 @default.
- W4200306712 cites W2116639751 @default.
- W4200306712 cites W2132738065 @default.
- W4200306712 cites W2168509026 @default.
- W4200306712 cites W2310716991 @default.
- W4200306712 cites W2345980114 @default.
- W4200306712 cites W2416844197 @default.
- W4200306712 cites W2616318316 @default.
- W4200306712 cites W2769212643 @default.
- W4200306712 cites W2886746356 @default.
- W4200306712 cites W2966775399 @default.
- W4200306712 cites W2990274749 @default.
- W4200306712 cites W3005404170 @default.
- W4200306712 cites W3025082678 @default.
- W4200306712 cites W3092613359 @default.
- W4200306712 cites W3106515863 @default.
- W4200306712 cites W3108724611 @default.
- W4200306712 cites W3126183384 @default.
- W4200306712 cites W3126968496 @default.
- W4200306712 cites W3129777853 @default.
- W4200306712 cites W3160786202 @default.
- W4200306712 cites W3185250096 @default.
- W4200306712 cites W3206950476 @default.
- W4200306712 cites W4251026925 @default.
- W4200306712 doi "https://doi.org/10.3390/cancers13246316" @default.
- W4200306712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34944936" @default.
- W4200306712 hasPublicationYear "2021" @default.
- W4200306712 type Work @default.
- W4200306712 citedByCount "1" @default.
- W4200306712 countsByYear W42003067122022 @default.
- W4200306712 crossrefType "journal-article" @default.
- W4200306712 hasAuthorship W4200306712A5000027373 @default.
- W4200306712 hasAuthorship W4200306712A5006583715 @default.
- W4200306712 hasAuthorship W4200306712A5012163855 @default.
- W4200306712 hasAuthorship W4200306712A5016734314 @default.
- W4200306712 hasAuthorship W4200306712A5018989526 @default.
- W4200306712 hasAuthorship W4200306712A5025198232 @default.
- W4200306712 hasAuthorship W4200306712A5038345056 @default.
- W4200306712 hasAuthorship W4200306712A5043947276 @default.
- W4200306712 hasAuthorship W4200306712A5044226126 @default.
- W4200306712 hasAuthorship W4200306712A5046597133 @default.
- W4200306712 hasAuthorship W4200306712A5055404021 @default.
- W4200306712 hasAuthorship W4200306712A5088881526 @default.
- W4200306712 hasAuthorship W4200306712A5089295627 @default.
- W4200306712 hasAuthorship W4200306712A5090832029 @default.
- W4200306712 hasBestOaLocation W42003067121 @default.
- W4200306712 hasConcept C104317684 @default.
- W4200306712 hasConcept C117643217 @default.
- W4200306712 hasConcept C121608353 @default.
- W4200306712 hasConcept C126322002 @default.
- W4200306712 hasConcept C142724271 @default.
- W4200306712 hasConcept C2776232967 @default.
- W4200306712 hasConcept C2777542201 @default.
- W4200306712 hasConcept C2777872185 @default.
- W4200306712 hasConcept C2778461978 @default.
- W4200306712 hasConcept C2778911148 @default.
- W4200306712 hasConcept C2779338263 @default.
- W4200306712 hasConcept C2779634585 @default.
- W4200306712 hasConcept C2780007613 @default.
- W4200306712 hasConcept C2781182431 @default.